Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Publication
Diabetologia 62(7):1154-1166 https://doi.org/10.1007/s00125-019-4859-4
Date